Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7654078 | 0.94 | GBA1 (0.48) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL6167695 | 0.83 | GBA1 (0.53) | GBA1SLC18A3CCR3CARM1PRMT6 | |
| SCHEMBL316482 | 0.82 | GBA1 (0.65) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL6290794 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL29013918 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL158625 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL28374076 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL8137977 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL1119456 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 | |
| SCHEMBL113380 | 0.80 | GBA1 (0.63) | GBA1SLC18A3CCR3POLBCARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273582-B1 | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents | PFIZER PROD INC (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1273580-B1 | Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6900230-B2 | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-6875779-B2 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1233959-B1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PROD INC (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040198735-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SAKYA SUBAS M (US) | 2004-10-07 | — | — | US | disclosed |
| US-6753332-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030236258-A1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030125368-A1 | Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents | SAKYA SUBAS M (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030119835-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | PFIZER PRODUCTS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-20030119836-A1 | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents | SAKYA SUBAS M (US) | 2003-06-26 | — | — | US | disclosed |
| US-6531492-B1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1273580-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1273576-A1 | Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1273582-A1 | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1233959-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | Pfizer Products Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040216-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125368-A1 | Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents | SULT2A1, AHR, SULT1A1 | GBA1 2080/4885SLC18A3 3927/4885CCR3 328/4885 |
| US-20030236258-A1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PTGS1, SULT2A1, PTGES3 | GBA1 2296/4885SLC18A3 4649/4885CCR3 500/4885 |
| US-20040198735-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SULT2A1, SULT1A1, SULT1E1 | GBA1 1781/4885SLC18A3 3841/4885CCR3 302/4885 |
| US-20030119836-A1 | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents | PTGS1, SULT2A1, AHR | GBA1 2074/4885SLC18A3 4677/4885CCR3 811/4885 |
| US-20030119835-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SULT2A1, SULT1A1, SULT1E1 | GBA1 1781/4885SLC18A3 3841/4885CCR3 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.